FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
10 | Prognostic value of trans epidermal water loss in the treatment of actinic keratoses. A comparison amongst topical therapies for field cancerization Matteo Bevilacqua, Filippo Fanetti, Nicolò Mori, Agata Janowska, Valentina Dini, Marco Romanelli | Department of Dermatology, University of Pisa, Pisa, Italy.
407 -
29 | The extracellular vesicle potential for the early detection of resistance to immunotherapy in melanoma patients Cristina Catoni1, Cristina Poggiana1, Alessandro Francesco Piazza1, Jacopo Pigozzo2, Luisa Piccin2, Chiara Menin1, Stefania Pellegrini1, Valentina Salizzato2, Paolo Del Fiore4, Simone Mocellin3|4, Vanna Chiarion-Sileni2, Valentina Guarneri2|3, Antonio Rosato1|3, Maria Chiara Scaini1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 2Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua; 3Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
306 -
16 | Sentinel lymph node biopsy in elderly patients with melanoma: prognostic value and impact on recurrence B. Taglione1, I. Mattavelli1, A. Maurichi1, G. Gallino1, D. Cortese1, A. Manfredi1, S. Mercurio1, G. Spadola1, E. Tolomio1, C. Barbieri1, B. Scoppio1, M. Cossa2, B. Valeri2, M. Santinami1, R. Patuzzo1 | 1IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Melanoma Surgical Unit, Milano; 2IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Pathology, Milano, Italy.
338 -
35 | Real-world outcomes of targeted therapy in stage IV melanoma after relapse on adjuvant dabrafenib and trametinib: insights from a single-center cohort Rossella Villani, Chiara Bungaro, Anna Cecere, Ileana De Roma, Sabino Strippoli, Michele Guida | Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
380 -
22 | Surgical radicality and reconstructive techniques in melanoma and non-melanoma skin cancer A. Lenta, A. Amore, L. Benedetto, C. Caracò | Chirurgia del Melanoma e dei tumori cutanei, Istituto Nazionale Tumori "Fondazione Pascale", Napoli, Italy.
356 -
06 | SUNTEL program: first experience of school integration of the ugly duckling sign with e-learning and peer education for melanoma awareness Giorgia Ravaglia1, Serena Magi2, Elisabetta Costa3, Matelda Medri2, Franca Gentilini4, Chiara Scutellà4, Daniela De Zerbi5, Silvia Gerosa1, Federica Zamagni6, Chiara Doccioli7, Sara Gandini8, Maria Costanza Cipullo9, Saverio Caini7, Ignazio Stanganelli1|2 | 1Dermatology Resident Training Program, Department of Medicine and Surgery, University of Parma, Parma; 2Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST Meldola, Forlì-Cesena; 3Graphic Design and Multimedia "Good Sun Good Skin" project, Istituto Oncologico Romagnolo, Forlì; 4IOR Scuola, Istituto Oncologico Romagnolo, Forlì; 5Scientific High School "Alfredo Oriani", Ravenna; 6Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS IRST Romagnolo Institute for the Study of Tumors "Dino Amadori", Meldola, Forlì-Cesena; 7Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention, and Clinical Network, ISPRO, Florence; 8Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan; 9Directorate General for Student Affairs, Inclusion, and Career Guidance, Prevention and Health Education Unit, Ministry of Education, Rome, Italy.
355 -
09 | Integration of hematoxylin and eosin and immunohistochemistry images to improve AI-based recurrence prediction in negative sentinel lymphnode melanoma patients Maria Colomba Comes1, Andrea Lupo1, Fabio Mele2, Concetta Saponaro2, Arianna Bozzi1, Ivana De Risi3, Samantha Bove1, Annarita Fanizzi1, Benedetta Apollonio3, Margherita Sonnessa2, Sabino Strippoli3, Francesco Alfredo Zito2, Michele Guida3, Raffaella Massafra1 | 1Biostatistics and Bioinformatics Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 2Pathology Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 3Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
342 -
28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study Miriam Forte1, Francesco Caraglia1, Silvana Cozzolino1, Antonino Colloca1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Francesca Sparano5, Maria Chiara Sergi3, Teresa Del Giudice4, Immacolata Paciolla6, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi6, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples; 2Department of Clinical Medicine and Surgery, Federico Il University, Naples; 3Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli", Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Napoli; 6Medical Oncology Unit AORN "San Pio", Benevento, Italy.
372 -
15 | Clinico-pathological features of superficial angiosarcomas: a retrospective study Lorenzo Bellando1, Chiara Anselmo2, Giulia Orlando3, Leonardo Panarelli2, Pietro Cosentino2, Pietro Quaglino4, Franco Picciotto5, Simone Ribero4, Rebecca Senetta3 | 1Pathology Unit, Città Della Salute e Della Scienza of Turin, University of Turin; 2Department of Medical Sciences, Pathology Unit, University of Turin; 3Department of Oncology, Pathology Unit, University of Turin; 4Department of Medical Sciences, Section of Dermatology, University of Turin; 5Department of Surgery, Dermatologic Surgery Section, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy.
353 -
34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo1|2, Bruna Dalmasso3, Maria Chiara Scaini4, Laura Cendron5, Monica Rodolfo6, Ilaria Mattavelli7, Elena Tamborini8, Francesca Collina9, Gerardo Ferrara, Gabriele Madonna10, Carlo Cota11, Elisa Melucci12, Stefania Tommasi13, Martina Ubaldi14, Roberta Depenni15, Andrea Carugno16, Riccardo Marconcini17, Laura Orgiano18, Maurizio Lombardo19, Simona Sola20, Cristina Pellegrini21, Francesca Castiglione22, Matteo Gasparotto5|23, Alireza Jorkesh5, Stefania Pellegrini4, Edoardo Raposio1, Andrea Boutros2, Enrica Teresa Tanda2, Michele Guida25, Pietro Quaglino26, Giuseppe Palmieri27, Daniela Massi22, Paolo Antonio Ascierto10, Mario Mandalà*28, Chiara Menin*4, Paola Ghiorzo*24, Lorenza Pastorino*24, for the Italian Melanoma Intergroup29 | 1Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; 2IRCCS Ospedale Policlinico San Martino, Genova; 3IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; 4Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; 5Department of Biology, University of Padua, Padua; 6Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 7Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 8Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 9Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; 10Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; 11Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; 12Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; 13Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; 14Unit of Medical Oncology, University of Perugia; 15Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; 16Department of Medicine and Surgery, University of Insubria, Varese; 17Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; 18Department of Medical Oncology, University of Cagliari, Cagliari; 19Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; 20Surgical Pathology, Galliera Hospital, Genoa; 21Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; 22Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; 23Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 24Department of Internal Medicine and Medical Specialties, University of Genoa; 25Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; 26Dermatology Clinic, Department of Medical Sciences, University of Turin; 27Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; 28University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; 29Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.
352 -
21 | Melanoma in situ: long-term outcomes and follow-up strategies based on risk stratification Beatrice De Checchi1, Paolo del Fiore2, Irene Russo2, Chiara Trevisiol2, Marco Domenico Mazza2, Saveria Tropea2, Francesco Russano2, Mauro Alaibac3, Carlomaria Gianesini4, Giovanni Madeo4, Simone Mocellin2|4 | 1Department of Medicine, University of Padua, Padua; 2Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 3Department of Dermatology, University of Padua; 4Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
361 -
05 | Revisiting cancer risk associated with the MITF p.e318k variant beyond melanoma Debora Tonello1, Beatrice Zennaro1, Stefania Pellegrini1, Monica Quaggio2, Luisa Piccin3, Alessio Fabozzi4, Luigi Dall’Olmo2|5, Saveria Tropea5, Maria Chiara Scaini1, Chiara Menin1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova; 2Department of Surgery, Oncology and Gastroenterology, Section of Immunology and Oncology, AIDS Reference Center, University of Padova, Padova; 3Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova; 4Oncology Unit 3, Veneto Institute of Oncology - IOV-IRCCS, Padua; 5Soft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
376 -
08 | Cutaneous melanoma and occupational UV exposure: associations with anatomical site, histological subtype, and Breslow thickness Federica Fazzari, Giovanni Cecchi, Gabriella Perill, Biancamaria Zuccaro, Vincenzo De Giorgi | Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
367 -
27 | Real-world data for malignant melanoma stage II adjuvant therapy Silvana Cozzolino1, Antonino Colloca1, Miriam Forte1, Francesco Caraglia1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Maria Chiara Sergi3, Teresa Del Giudice4, Francesca Sparano5, Immacolata Paciolla6, Mariangela Pasqualoni7, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi1, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples; 2Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy; 3Division of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples; 6Medical Oncology Unit, AORN "San Pio", Benevento, Italy; 7Medical Oncology Unit, ASL Taranto, Italy.
364
